Objectives:

1. Make use of harm reduction principles in caring for patients with cancer and substance use disorders
2. Identity patients with cancer for whom buprenorphine should be the first line opioid analgesic
3. Formulate a plan to safely transition an opioid tolerant patient to buprenorphine therapy

Join from a PC, Mac, iPad, iPhone or Android device:

    Please click this URL to join. https://uwmadison.zoom.us/s/98999974393?pwd=dWpBbHUwNDliMEtlYXNOak5IRnZzdz09

    Passcode: Grand

                Description: Presenter to be announced

Or One tap mobile:

    +13126266799,,98999974393# US (Chicago)

    +16469313860,,98999974393# US

Or join by phone:

    Dial(for higher quality, dial a number based on your current location):

        US: +1 312 626 6799  or +1 646 931 3860  or +1 929 205 6099  or +1 301 715 8592  or +1 309 205 3325  or +1 386 347 5053  or +1 564 217 2000  or +1 669 444 9171  or +1 669 900 6833  or +1 719 359 4580  or +1 253 215 8782  or +1 346 248 7799

    Webinar ID: 989 9997 4393

    International numbers available: https://uwmadison.zoom.us/u/ac9BqmRRQX

Or an H.323/SIP room system:

    H.323: 162.255.37.11 (US West) or 162.255.36.11 (US East)

    Webinar ID: 989 9997 4393

    Passcode: 564520

    SIP: [email protected]

    Passcode: 564520